Glenmark Pharmaceuticals Surges on Launching Multi-Country Phase 3 Trial for Envafolimab
Mumbai, September 5 (Kiran News) — Shares of Glenmark Pharmaceuticals rose on Friday after the company announced it has initiated a multi-country Phase 3 clinical trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC). At 11:00 am, the stock was trading at ₹2,045.75, up 2.77% … Read more
